Aayush GuptaMultibacillary leprosy
Bedaquiline with rifampicin and clofazimine (LIGHT)
Dr Aayush Gupta is the principal investigator at Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune for a phase 3 study of bedaquiline with rifampicin and clofazimine (LIGHT) in multibacillary leprosy, sponsored by Johnson & Johnson. Status: under way since January 2025.
- Phase
- Phase 3
- Sponsor
- Johnson & Johnson
- Status
- Under way since January 2025
- Principal investigator
- Dr Aayush Gupta
- Site
- Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune
- Condition
- Multibacillary leprosy
Official title
A Phase 3, Multicenter, Open-label, Rater-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline for the Treatment of Multibacillary Leprosy When Combined With Rifampicin and Clofazimine [LIGHT]
Research programme
He is the principal investigator at Dr. D.Y. Patil on LIGHT, a Phase 3 Johnson & Johnson trial of bedaquiline in multibacillary leprosy, and on a Phase 0 study of plasma PGL-I for treatment monitoring. His clinical papers cover leprosy, the differential diagnosis of leonine facies, scrofuloderma and nodular secondary syphilis with granulomatous inflammation.
Related papers
15 in this area
- Comment on Case Series of Kaposi’s Varicelliform Eruption Associated with Underlying Primary DermatosesIndian Journal of Dermatology2026Senior authorDOI
- Global, regional, and national burden of HIV/AIDS, 1990–2023, with the estimated burden attributable to intimate partner violence and forecasted impacts of funding cuts through 2030: results from the Global Burden of Disease Study 2023The Lancet HIV2026DOI
- Revisiting Leonine Facies: Toward More Inclusive Differential DiagnosesIndian Dermatology Online Journal2026Senior authorDOI
- Internalized stigma, not disability, drives quality‐of‐life loss in leprosy: A structural analysisJournal of the European Academy of Dermatology and Venereology2026Senior authorDOI
- A Within-Person Randomized Controlled Pilot Study to Evaluate the Ability of a Point-of-Care Artificial Intelligence-Enabled Multispectral Imaging Device to Manage Leg Ulcers in LeprosyAdvances in Skin & Wound Care2025Senior authorDOI
- Borderline Tuberculoid LeprosyJEADV Clinical Practice2025Senior authorDOI
Other trials
- Placebo-controlled · Sun PharmaSevere alopecia areata in adolescentsSubmitted to DCGI
- Phase 0 · Johnson & JohnsonMultibacillary leprosy, treatment monitoringOpens October 2026
- Phase 2 · Ahammune BiosciencesNon-segmental vitiligoOpens October 2026
- Observational · Systopic LaboratoriesHair health in adultsOpens October 2026
- Phase 4 · Johnson & JohnsonPsoriasisOpens November 2026
- Registry · PfizerAtopic dermatitis, alopecia areata and vitiligoStarted March 2025, completed